



## Hybrid Multifunctional Drug Delivery Systems

Guest Editors:

**Assist. Prof. Alexandra Teleki**

Department of Pharmacy,  
Uppsala University, Uppsala,  
Sweden

[alexandra.teleki@farmaci.uu.se](mailto:alexandra.teleki@farmaci.uu.se)

**Prof. Jessica Rosenholm**

Pharmaceutical Sciences  
Laboratory, Faculty of Science  
and Engineering, Åbo Akademi  
University, Turku, Finland

[jerosenh@abo.fi](mailto:jerosenh@abo.fi)

**Assoc. Prof. Line Hagner  
Nielsen**

Department of Health  
Technology, Technical University  
of Denmark, Lyngby, Denmark

[lihan@dtu.dk](mailto:lihan@dtu.dk)

Deadline for manuscript  
submissions:

**15 May 2020**

### Message from the Guest Editors

Dear Colleagues,

The vast array of today's nano- and microparticle platforms include polymeric nanoparticles, lipid carrier systems as well as different types of inorganic particles. Hybrid drug carriers are the next frontier in the development of novel, multifunctional drug delivery systems, as they benefit from the synergistic properties of the individual components. Typical examples include functionalization of inorganic particles with organic constructs combining structural robustness with functional responsiveness. This course of action is usually taken in order to enhance drug encapsulation efficiency and to control drug release, or for the design of theranostic nanomaterials for simultaneous imaging and therapy.

This Special Issue aims to highlight recent advances in hybrid multifunctional drug delivery systems, with a focus on particle-based systems, ranging from synthesis methods and process understanding, their detailed physicochemical characterization and performance in vitro and in vivo, especially for controlled and/or targeted drug delivery applications.

Assist. Prof. Alexandra Teleki  
Prof. Jessica Rosenholm  
Assoc. Prof. Line Hagner Nielsen  
Guest Editors





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Yvonne Perrie

Strathclyde Institute of Pharmacy  
and Biomedical Sciences,  
University of Strathclyde,  
Glasgow, UK

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High visibility:** indexed by the Science Citation Index Expanded (Web of Science), BIOSIS Previews and Scopus (CiteScore: 4.58). Citations available in PubMed, full-text archived in PubMed Central.

**Rapid publication:** manuscripts are peer-reviewed and a first decision provided to authors approximately 15.2 days after submission; acceptance to publication is undertaken in 3.9 days (median values for papers published in this journal in the first half of 2019).

## Contact Us

---

*Pharmaceutics*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
Fax: +41 61 302 89 18  
www.mdpi.com

mdpi.com/journal/pharmaceutics  
pharmaceutics@mdpi.com  
@MDPIpharma